Shots:VERAXA to reverse merge with Voyager, where the combined entity- "VERAXA Biotech” will be listed on Nasdaq under VERX ticker; closing expected in Q4’25As per the deal, VERAXA will have access to ~$253M cash from Voyager’s trust at closing & contribute ~$1.3B in equity for ~130M shares, with all shareholders rolling over 100%…
There are tons of clinical trials taking place at this moment. It’s a nasty disease and it’s important to figure out different ways to diagnose it, treat it, and, if possible, prevent it. 2024 brings on innovations in this field.It can probably shed light on how cancer can become more treatable and not such…

